Track market-moving stories before they get noisy

Posted by Defense World Staff on Jul 21st, 2026

Fifth Third Bancorp grew its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 51.2% during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 17,733 shares of the medical research company’s stock after acquiring an additional 6,002 shares during the quarter. Fifth Third Bancorp’s holdings in Charles River Laboratories International were worth $3,059,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in CRL. Tema Etfs LLC bought a new position in Charles River Laboratories International during the fourth quarter valued at approximately $26,000. Los Angeles Capital Management LLC bought a new stake in shares of Charles River Laboratories International in the fourth quarter worth $42,000. Sfam LLC purchased a new stake in Charles River Laboratories International during the fourth quarter valued at $43,000. Activest Wealth Management increased its position in Charles River Laboratories International by 10,900.0% during the fourth quarter. Activest Wealth Management now owns 220 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 218 shares during the last quarter. Finally, Elyxium Wealth LLC bought a new position in Charles River Laboratories International in the fourth quarter valued at about $46,000. 98.91% of the stock is currently owned by institutional investors.

Insiders Place Their Bets In related news, Director James C. Foster sold 75,000 shares of the firm’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $225.00, for a total transaction of $16,875,000.00. Following the completion of the transaction, the director directly owned 31,596 shares of the company’s stock, valued at approximately $7,109,100. This trade represents a 70.36% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In Several brokerages have recently weighed in on CRL. Mizuho increased their price objective on shares of Charles River Laboratories International from $192.00 to $230.00 and gave the stock a “neutral” rating in a research note on Monday, July 13th. Royal Bank Of Canada initiated coverage on shares of Charles River Laboratories International in a research report on Tuesday, April 14th. They set an “outperform” rating and a $215.00 target price for the company. Barclays upped their target price on shares of Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a report on Friday, May 8th. Sanford C. Bernstein set a $250.00 price target on shares of Charles River Laboratories International in a research note on Wednesday, July 1st. Finally, Robert W. Baird set a $213.00 target price on Charles River Laboratories International in a report on Friday, May 8th. Eleven research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $220.75.

View Our Latest Stock Report on Charles River Laboratories International

Charles River Laboratories International Trading Down 2.0% Shares of CRL stock opened at $219.91 on Tuesday. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The stock has a fifty day simple moving average of $193.76 and a two-hundred day simple moving average of $186.77. The firm has a market capitalization of $10.59 billion, a PE ratio of -58.49, a PEG ratio of 2.50 and a beta of 1.40. Charles River Laboratories International, Inc. has a 52-week low of $144.26 and a 52-week high of $237.86.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The business had revenue of $995.83 million during the quarter, compared to analyst estimates of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company’s revenue was up 1.2% on a year-over-year basis. During the same period last year, the firm posted $2.34 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. On average, analysts predict that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

Charles River Laboratories International Profile (Free Report)

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.

Read More Five stocks we like better than Charles River Laboratories International The Ugliest Stocks in the Market Just Got a Very Expensive Vote of Confidence Is Domino’s Stock Serving Up a Buying Opportunity? A $1T Black Hole: SpaceX Eyes Pentagon AI to Break Free Why Gold Miners Could Be the Market’s Biggest Comeback Story

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEMicrosoft Corporation $MSFT Shares Sold by Geneva Partners LLC

NEXT HEADLINE »DICK’S Sporting Goods, Inc. $DKS Shares Sold by Bank of New York Mellon Corp

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? Charles River Laboratories (CRL - Free Report) , which belongs to the Zacks Medical Services industry, could be a great candidate to consider.

This medical research equipment and services provider has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for the last two quarters was 3.84%.

For the last reported quarter, Charles River came out with earnings of $2.06 per share versus the Zacks Consensus Estimate of $1.96 per share, representing a surprise of 5.10%. For the previous quarter, the company was expected to post earnings of $2.33 per share and it actually produced earnings of $2.39 per share, delivering a surprise of 2.58%.

Price and EPS Surprise

With this earnings history in mind, recent estimates have been moving higher for Charles River. In fact, the Zacks Earnings ESP (Expected Surprise Prediction) for the company is positive, which is a great sign of an earnings beat, especially when you combine this metric with its nice Zacks Rank.

Our research shows that stocks with the combination of a positive Earnings ESP and a Zacks Rank #3 (Hold) or better produce a positive surprise nearly 70% of the time. In other words, if you have 10 stocks with this combination, the number of stocks that beat the consensus estimate could be as high as seven.

The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the quarter; the Most Accurate Estimate is a version of the Zacks Consensus whose definition is related to change. The idea here is that analysts revising their estimates right before an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier.

Charles River currently has an Earnings ESP of +1.43%, which suggests that analysts have recently become bullish on the company's earnings prospects. This positive Earnings ESP when combined with the stock's Zacks Rank #3 (Hold) indicates that another beat is possibly around the corner.

Investors should note, however, that a negative Earnings ESP reading is not indicative of an earnings miss, but a negative value does reduce the predictive power of this metric.

Many companies end up beating the consensus EPS estimate, though this is not the only reason why their shares gain. Additionally, some stocks may remain stable even if they end up missing the consensus estimate.

Because of this, it's really important to check a company's Earnings ESP ahead of its quarterly release to increase the odds of success. Make sure to utilize our Earnings ESP Filter to uncover the best stocks to buy or sell before they've reported.

Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company,

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Shareholders should contact the firm immediately as there may be limited time to enforce your rights. 

, /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Charles River Laboratories International, Inc. (NYSE: CRL) breached their fiduciary duties to shareholders.

If you currently own Charles River stock and are a long-term shareholder, you may be able to seek corporate governance reforms, the return of funds back to the company, a court-approved financial incentive award, or other relief and benefits. Please click here to learn more about your legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or [email protected] or [email protected].

Why Your Participation Matters:

Shareholder involvement can help improve a company's policies, practices, and oversight mechanisms to create a more transparent, accountable, and effectively managed organization, which can enhance shareholder value.

Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:
Halper Sadeh LLC
One World Trade Center
85th Floor
New York, NY 10007
Daniel Sadeh, Esq.
Zachary Halper, Esq.
(212) 763-0060
[email protected]
[email protected]
https://www.halpersadeh.com

SOURCE Halper Sadeh LLP

Key Takeaways Charles River is supported by RMS strength, broader CRADL adoption and focused portfolio actions.CRL completed CDMO and Cell Solutions divestitures and repurchased $200M of stock in Q1 2026.CRL faces soft biopharma demand and foreign exchange headwinds that may weigh on 2026 results. Charles River Laboratories International, Inc. (CRL - Free Report) is well-poised to grow in the coming quarters owing to the strength of its Research Models and Services (“RMS”) business and broader CRADL adoption. Strategic deals continue to broaden its capabilities while streamlining its portfolio. The company maintains a solid financial position, which is also highly encouraging. Yet, persistent soft biopharma demand trends and adverse currency swings may hurt Charles River’s results of operations.

Over the past year, this Zacks Rank #3 (Hold) stock has rallied 44.6% compared with the industry’s 9.6% rise and the S&P 500 composite’s 23% growth.

The renowned, non-clinical global drug development company has a market capitalization of $10.87 billion. Charles River has an earnings yield of 4.9%, which compares favorably with the industry’s 4.1% yield. It surpassed estimates in each of the trailing four quarters, delivering an average earnings surprise of 9.31%.

Let’s delve deeper.

Upsides for CRL StockRMS Prospects Seem Bright: Charles River continues to maintain its position as a global leader in the production and sale of widely used research models. Small research models remain a cost-effective tool for biomedical research, supporting the company’s ability to implement pricing actions across geographies over time.

In the first quarter of 2026, management highlighted continued demand for small models in China from mid-tier biotech and CRO clients and emphasized that RMS results can vary from quarter to quarter based on the timing of large-model shipments. Charles River’s CRADL model also continues to appeal to clients seeking flexible vivarium space without having to build internal infrastructure, with its value proposition becoming even more attractive as clients prioritize capital efficiency.

Image Source: Zacks Investment Research

Strategic Deals Drive Growth: Charles River is reshaping its portfolio to focus on areas where it has differentiated scientific capabilities. The company completed the previously announced divestiture of its contract development and manufacturing organization (CDMO) and Cell Solutions businesses on May 6, 2026.  CRL continues to use collaborations and selective acquisitions to broaden its capabilities across the discovery-to-development continuum while maintaining a more focused go-forward portfolio.

Its strategic collaborations within its CDMO, including partnerships with the Parker Institute for Cancer Immunotherapy, Children's Hospital Los Angeles and the Gazi University Faculty of Medicine, are aimed at advancing novel oncology research and development. In 2025, Charles River participated in several collaborations, including those with Toxys, X-Chem and the Francis Crick Institute, among others.

A Stable Solvency Structure: Charles River exited the first quarter of 2026 with cash and cash equivalents of $191.8 million, and no short-term debt payable on its balance sheet. The company continues to balance investment, shareholder returns and funding needs. Charles River also repurchased $200 million of stock under the $1.0 billion authorization, leaving $800 million remaining at quarter-end. 

Factors Affecting Charles RiverBiopharma Demand Remains Soft: Charles River continues to face a cautious spending environment, particularly among global biopharmaceutical and biotechnology clients within the DSA segment, as customers reassess budgets, reprioritize drug pipelines and manage cost structures. While management characterized the biopharma demand environment as stabilizing, spending levels are yet to return to prior norms.

First-quarter 2026 organic revenues declined 1.5%, reflecting pressure in RMS and discovery services. Management also noted that revenues from small and mid-sized biotech clients dropped during the quarter due to the lagged impact of softer DSA bookings in mid-2025, highlighting that improved funding conditions do not translate into revenues immediately.

Foreign Exchange Can Obscure Underlying Trends: Foreign currency translation increased Charles River’s reported first-quarter 2026 revenues by 2.8%, partially masking the underlying organic decline. Management also lowered its 2026 reported revenue outlook by approximately 50 basis points due to updated foreign exchange assumptions. Given the company’s sizable international footprint, foreign exchange volatility can create discrepancies between reported and organic performance and make period-to-period comparisons more challenging.

CRL Stock Estimate TrendThe Zacks Consensus Estimate for CRL’s 2026 earnings has increased 1 cent to $11.05 in the past 30 days.

The Zacks Consensus Estimate for the company’s 2026 revenues is pegged at $3.83 billion, suggesting a 4.5% decrease from the year-ago reported number.

Key PicksSome better-ranked stocks in the broader medical space are Globus Medical (GMED - Free Report) , Align Technology (ALGN - Free Report) and Integra LifeSciences (IART - Free Report) .

Globus Medical has an earnings yield of 5.9% compared to the industry’s negative 3.5% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 26.3%. GMED shares have rallied 27.8% against the industry’s 10.9% decline over the past year.

GMED carries a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Align Technology, carrying a Zacks Rank #2, has an estimated long-term earnings growth rate of 10.3% compared with the industry’s 5.5% growth. Shares of the company have dipped 15.3% against the industry’s 9.1% growth. ALGN’s earnings outpaced estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 7.8%.

Integra LifeSciences, carrying a Zacks Rank #2, has an earnings yield of 13.6% against the industry’s negative 3.5% yield. Its earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, with the average surprise being 16.7%. IART shares have rallied 33.3% against the industry’s 10.9% decline over the past year.

HomeStock IdeasLong IdeasHealthcare 

SummaryAchieve Life Sciences remains a cytisinicline story, with very positive smoking-cessation data. This also gives cytisinicline some added optionality for vaping.The FDA's CRL appears to be mostly about manufacturing and labeling issues. However, it’s not about a particular cytisinicline efficacy or safety problem.ACHV is currently targeting Q4 2026 resubmission and, assuming everything goes according to plan, it could receive approval by 1H2027.ACHV’s recent capital raise in April also helped their runway and gives them flexibility in case there are more setbacks going forward.As such, I believe ACHV has the resources and ingredients to prove that cytisinicline can work for nicotine addiction. So, I remain bullish on the stock long-term.Iryna Melnyk/iStock via Getty Images

Achieve Life Sciences, Inc. (ACHV) is a pharmaceutical company that is developing cytisinicline. This is a smoking cessation medication, which has so far shown promising results in two Phase 3 trials. In theory, cytisinicline could eventually address both

3.47K Followers

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

-

Collaboration supports Charles River’s strategic goals to build deeper client relationships to further modernize R&D through innovative technologies

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) announced a collaboration with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (Lilly).

"The combination of Charles River’s decades-long expertise in nonclinical testing with TuneLab’s innovative AI/ML models will support the accelerated development of innovative therapeutics."

Share TuneLab was created to accelerate biotech innovation by enabling participating companies to access AI/ML drug discovery models trained on decades of Lilly's proprietary research data, in exchange for data contributions that improve model performance through federated learning. Participating companies may use the TuneLab prediction models to more rapidly down-select candidate molecules. Through this collaboration, Charles River will provide nonclinical testing services to TuneLab companies.

“The combination of Charles River’s decades-long expertise in nonclinical testing with TuneLab’s innovative AI/ML models will support the accelerated development of innovative therapeutics,” said Dr. Namandjé N. Bumpus, Chief Science and Innovation Officer, Charles River. “TuneLab’s collaborative AI platform democratizes access to pharma-grade tools, relieving a substantial resource burden for biotechs. By layering in Charles River’s industry-leading hands-on research experience, TuneLab participants have access to additional validation that supports discovery decision-making.”

Standardizing protocols with nonclinical testing across the TuneLab ecosystem should enable the AI/ML models to learn more efficiently from the ongoing contributions, improving the models further and increasing the efficiency of the TuneLab platform.

Lilly TuneLab is part of Lilly Catalyze360, alongside Lilly Ventures, Lilly Gateway Labs, and Lilly ExploR&D, which together support biotech innovation by providing access to strategic capital, lab space and technology, and research and development capabilities.

Charles River remains committed to advancing the validation and acceptance of new approach methodologies (NAMs), including through its Alternative Methods Advancement Project™ (AMAP™) initiative. Together with clients, regulators, and industry, NAMs provide a foundation for a future where more patients gain access to life-saving treatments—safely, swiftly, and with reduced reliance on animal use in research where scientifically appropriate.

About the Alternative Methods Advancement Project (AMAP)

The Alternative Methods Advancement Project (AMAP) is a Charles River-led initiative dedicated to developing New Approach Methodologies (NAMs) and exploring innovative scientific and technological solutions aimed at reducing reliance on traditional animal testing. As we enter the next frontier of drug development, AMAP enables strategic, purpose-driven investment to shape a future in which more patients can access the treatments and medicines they need safely, swiftly, and successfully. AMAP is supported by our global, cross-functional Scientific Advisory Board led by Dr. Namandjé N. Bumpus.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

More News From Charles River Laboratories International, Inc.

Back to Newsroom

Key Takeaways CRL posted Q1 adjusted EPS of $2.06 and revenues of $995.8M, both above estimates.Charles River saw gross margin fall 269 bps and adjusted operating margin contract 64 bps.CRL reaffirmed 2026 guidance and completed the CDMO and Cell Solutions divestiture. Charles River Laboratories International, Inc. (CRL - Free Report) reported first-quarter 2026 adjusted earnings per share (EPS) of $2.06, down 12% year over year. The figure surpassed the Zacks Consensus Estimate by 5.1%.

On a GAAP basis, the company reported a loss of 30 cents per share compared with the year-ago quarter’s earnings of 50 cents.

CRL’s RevenuesRevenues totaled $995.8 million, which beat the Zacks Consensus Estimate by 2.5%. The top line rose 1.2% from the year-ago quarter’s level (down 1.5% organically, excluding the impact of foreign currency translation and the divestiture of a small Safety Assessment site in 2024).

Following the announcement, CRL shares fell 0.7% in the pre-market trading today.

CRL’s Q1 Segmental Performance in DetailThe company reports under three segments — Research Models and Services (“RMS”), Discovery and Safety Assessment (“DSA”) and Manufacturing Solutions.

RMS’ revenues totaled $208.4 million, down 2.2% year over year (down 5.5% organically). The organic decrease was mainly due to lower revenues for large research models and small research models in North America. Our model estimated RMS’ revenues to be $209.8 million in the first quarter.

DSA’s revenues amounted to $596.9 million, up 0.7% year over year (down 1.4% organically). The organic decline in revenues was primarily due to lower revenues for discovery services, partly from the impact of prior site consolidation activities. Our model projected revenues of $579.9 million for this segment.

Manufacturing Solutions’ revenues totaled $190.5 million, up 6.8% year over year (up 2.9% organically). The organic growth was due to higher revenues in the Microbial Solutions business. Our model projected revenues to be $194.9 million for the first quarter.

CRL’s Margin PerformanceThe gross profit in the reported quarter was $294.7 million, down 7.3% from the prior-year quarter’s level. The gross margin of 29.6% fell 269 basis points (bps) year over year.

Selling, general & administrative expenses dropped 10.3% year over year to $159.4 million. The adjusted operating profit totaled $135.2 million, down 3.4% from the prior-year quarter’s level. The adjusted operating margin contracted 64 bps to 13.6%.

CRL’s Liquidity PositionCharles River exited the first quarter of 2026 with cash and cash equivalents of $191.8 million compared with $213.8 million at the end of 2025.

Cumulative net cash provided by operating activities at the end of the first quarter was $41.1 million compared with $171.7 million a year ago.

During the first quarter of 2026, Charles River repurchased 1.1 million shares for a total of $200.0 million. As of March 28, 2026, it had $800.0 million remaining under its $1.0 billion stock repurchase authorization that was approved by the board of directors on Oct. 29, 2025.

CRL’s Divestiture UpdateOn May 6, 2026, Charles River completed the divestiture of the CDMO and Cell Solutions businesses to GI Partners. It expects to complete the sale of certain European Discovery Services sites in May 2026. These strategic transactions are expected to help the company refocus its comprehensive portfolio on core competencies and drive synergistic growth in areas in which it has differentiated scientific expertise.

Charles River’s 2026 GuidanceThe company last updated its full year guidance on Feb. 25, 2026, including the expected impact of the completed divestiture of the CDMO and Cell Solutions businesses, and the planned divestiture of certain European Discovery Services sites in May 2026.

Reported revenues for the year are now expected to grow (5.5)% - (4)%, from the previous (5.0)% - (3.5)% forecast. The Zacks Consensus Estimate for 2026 revenues is pegged at $3.97 billion, implying a 1.3% fall. 

Adjusted EPS for 2026 is expected in the range of $10.80-$11.30. The Zacks Consensus Estimate for the metric is pegged at $10.97.

Our Take on CRLCharles River exited the first quarter of 2026 with earnings and revenues beating estimates. The company delivered on the quarter’s targets and remains well-positioned to generate improving results throughout the year. By segment, organic revenue growth in the Manufacturing Solution was more than offset by organic revenue declines in the RMS and DSA segments. The contraction of both margins in the quarter is also discouraging.

Charles River reduced its 2026 reported revenue outlook by roughly 50 bps to reflect recent changes in assumptions for foreign exchange rates.

CRL’s Zacks Rank and Key Picks

Charles River currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are BrightSpring Health Services (BTSG - Free Report) , Intuitive Surgical (ISRG - Free Report) and Labcorp Holdings (LH - Free Report) .

BrightSpring Health Services, currently carrying a Zacks Rank #2 (Buy), reported first-quarter 2026 adjusted EPS of 36 cents, which surpassed the Zacks Consensus Estimate by 34.5%. Revenues of $3.61 billion beat the Zacks Consensus Estimate by 8.35%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

BTSG has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth. The company topped earnings estimates in three of the trailing four quarters and missed on one occasion, the average surprise being 14.61%.

Intuitive Surgical,carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $2.50, exceeding the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion outpaced the Zacks Consensus Estimate by 6.2%.

ISRG has an earnings yield of 2.1% compared to the industry’s negative 0.9% yield. The company’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 16.82%.

Labcorp,carrying a Zacks Rank #2 at present, posted first-quarter 2026 adjusted EPS of $4.25, exceeding the Zacks Consensus Estimate by 3.8%. Revenues of $3.54 billion outperformed the Zacks Consensus Estimate by 1%.

LH has an earnings yield of 6.9% compared with the industry’s 4.5% yield. The company’s earnings topped estimates in each of the trailing four quarters, the average surprise being 3.31%.

Charles River Laboratories International, Inc. (CRL) Q1 2026 Earnings Call Transcript

Charles River Laboratories International, Inc. (NYSE:CRL) posted upbeat earnings for the first quarter, but lowered its FY2026 forecast on Thursday.

The company posted adjusted EPS of $2.06, beating market estimates of $1.94. The company's sales came in at $995.830 million versus expectations of $977.486 million.

Charles River slashed its FY2026 GAAP EPS guidance from $6.30-$6.80 to $5.35-$5.85. The company also lowered its FY2026 sales guidance from $3.814 billion-$3.874 billion to $3.794 billion-$3.854 billion.

Birgit Girshick, Chief Executive Officer, said, “We are pleased to deliver on our first-quarter financial targets, and remain well positioned to generate improving results over the course of the year. Our confidence is supported by a DSA demand environment that is tracking to our expectations, resulting in solid bookings in the first quarter, as well as the successful execution of our strategy.”

Charles River shares fell 2.4% to trade at $177.25 on Friday.

These analysts made changes to their price targets on Charles River following earnings announcement.

Evercore ISI Group analyst Ross Muken maintained Charles River with an Outperform rating and raised the price target from $200 to $220. Barclays analyst Luke Sergott maintained the stock with an Overweight rating and raised the price target from $210 to $220. Considering buying CRL stock? Here’s what analysts think:

Photo via Shutterstock

Market News and Data brought to you by Benzinga APIs

© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

To add Benzinga News as your preferred source on Google, click here.

MarketBeat Instant News Alerts Trending News All MarketBeat Instant News Alerts Sort By

Time Frame

Alert Type

Keywords

Page 1 of 322

Get 30 Days of MarketBeat All Access for Free

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools.

Start Your 30-Day Trial

Sign in to your free account to enjoy these benefits

In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer.

Have you evaluated the performance of Charles River Laboratories' (CRL - Free Report) international operations for the quarter ending March 2026? Given the extensive global presence of this medical research equipment and services provider, analyzing the patterns in international revenues is crucial for understanding its financial strength and potential for growth.

In the current era of a tightly interconnected global economy, the proficiency of a company to penetrate international markets significantly influences its financial health and trajectory of growth. For investors, the key is to grasp how reliant a company is on overseas markets, as this provides insights into the durability of its earnings, its ability to exploit different economic cycles, and its overall growth capabilities.

Being present in foreign markets serves as protection against local economic declines and helps benefit from more rapidly expanding economies. Yet, such expansion also introduces challenges related to currency fluctuations, geopolitical uncertainties and varied market behaviors.

Our review of CRL's last quarterly performance uncovered some notable trends in the revenue contributions from its international markets, which are commonly analyzed and tracked by Wall Street experts.

The company's total revenue for the quarter stood at $995.83 million, increasing 1.2% year over year. Now, let's delve into CRL's international revenue breakdown to gain insights into the significance of its operations beyond home turf.

A Dive into CRL's International Revenue TrendsCanada generated $109.57 million in revenues for the company in the last quarter, constituting 11% of the total. This represented a surprise of -2.94% compared to the $112.88 million projected by Wall Street analysts. Comparatively, in the previous quarter, Canada accounted for $123.28 million (12.4%), and in the year-ago quarter, it contributed $125.35 million (12.7%) to the total revenue.

Europe accounted for 27.9% of the company's total revenue during the quarter, translating to $277.58 million. Revenues from this region represented a surprise of +5.64%, with Wall Street analysts collectively expecting $262.77 million. When compared to the preceding quarter and the same quarter in the previous year, Europe contributed $279.9 million (28.2%) and $263.25 million (26.8%) to the total revenue, respectively.

Of the total revenue, $9.4 million came from Other International, including Brazil and Israel during the last fiscal quarter, accounting for 0.9%. This represented a surprise of -20.98% as analysts had expected the region to contribute $11.89 million to the total revenue. In comparison, the region contributed $16.79 million, or 1.7%, and $16.67 million, or 1.7%, to total revenue in the previous and year-ago quarters, respectively.

During the quarter, Asia Pacific contributed $55.48 million in revenue, making up 5.6% of the total revenue. When compared to the consensus estimate of $42.48 million, this meant a surprise of +30.61%. Looking back, Asia Pacific contributed $56.91 million, or 5.7%, in the previous quarter, and $41.94 million, or 4.3%, in the same quarter of the previous year.

International Revenue PredictionsWall Street analysts expect Charles River to report $1 billion in total revenue for the current fiscal quarter, indicating a decline of 2.7% from the year-ago quarter. Canada, Europe, Other International, including Brazil and Israel and Asia Pacific are expected to contribute 12.4% (translating to $124.71 million), 27.1% ($272.09 million), 0.7% ($6.85 million), and 5.4% ($54.2 million) to the total revenue, respectively.

For the entire year, the company's total revenue is forecasted to be $4.01 billion, which is a reduction of 0.1% from the previous year. The revenue contributions from different regions are expected as follows: Canada will contribute 12.2% ($489.12 million), Europe 27% ($1.08 billion)Other International, including Brazil and Israel 1.1% ($45.04 million) and Asia Pacific 5% ($200.56 million) to the total revenue.

Final ThoughtsCharles River's reliance on international markets for revenues offers both opportunities and risks. Hence, keeping an eye on its international revenue trends could significantly help forecast the company's prospects.

In an environment where global interconnections and geopolitical skirmishes are intensifying, Wall Street analysts keep a keen eye on these trends, particularly for firms with overseas operations, to adjust their earnings predictions. Moreover, a range of other aspects, including how a company fares in its home country, significantly affects these projections.

Here at Zacks, we put a great deal of emphasis on a company's changing earnings outlook, as empirical research has shown that's a powerful force driving a stock's near-term price performance. Quite naturally, the correlation is positive here -- an upward revision in earnings estimates drives the stock price higher.

The Zacks Rank, our proprietary stock rating mechanism, demonstrates a notable performance history confirmed through external audits. It effectively utilizes the power of earnings estimate revisions to act as a predictor of a stock's price performance in the near term.

At present, Charles River holds a Zacks Rank #3 (Hold). This ranking implies that its near-term performance might mirror the overall market movement. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .

Examining the Latest Trends in Charles River Laboratories' Stock ValueOver the past month, the stock has seen an increase of 1.1% in its value, whereas the Zacks S&P 500 composite has posted an increase of 9.1%. The Zacks Medical sector, Charles River's industry group, has descended 2.9% over the identical span. In the past three months, there's been an increase of 10.1% in the company's stock price, against a rise of 7.1% in the S&P 500 index. The broader sector has declined by 9.8% during this interval.

-

Partnership showcases a forward-looking collaboration model that highlights advanced testing expertise

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories (CRL) and MEDIPOST Co., Ltd. (KOSDAQ 078160) have entered into a strategic, non-exclusive Memorandum of Understanding (MOU) to collaborate on GMP-compliant testing, as well as broader commercial and marketing efforts to advance cell therapy development and commercialization. The partnership will leverage Charles River’s expertise in biologics and cell therapy GMP testing to support MEDIPOST’s global cell therapy pipeline, starting in the Asia-Pacific (APAC) and North America (NA) regions, with possible expansion into Middle East and Europe.

“By collaborating with industry leaders, we aim to expand GMP testing capabilities and help ensure that safe, compliant products reach patients more efficiently.”

Share “We are excited to deepen our partnership with MEDIPOST and collaborate with a top global cell therapy developer, assisting at both clinical and commercialization phases,” said Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River. “By collaborating with industry leaders, we aim to expand GMP testing capabilities and help ensure that safe, compliant products reach patients more efficiently.”

Charles River will provide specialized expertise in biologics quality control, viral testing, release testing, and other GMP-compliant services, supporting MEDIPOST from development through commercialization. Through this non-exclusive MOU, Charles River continues to advance efficient, high-quality, and compliant development pathways for advanced biologics, particularly within the APAC region. The collaboration reflects a shared commitment to accelerating access to safe, effective cell therapies across global markets.

“We are pleased to announce this collaborative partnership with Charles River Laboratories, a true global-standard player and services provider in the field of biologics research and development,” said Antonio (Tony) Lee, Global President and Board Director at MEDIPOST.

“With over 14 years of commercial-stage allogeneic cell therapy product manufacturing and release experience, treating more than 36,000 patients within South Korea, MEDIPOST is now expanding into global regions starting with APAC and North America. Our partnership with Charles River will help us pave solid paths to efficient and compliant commercial pathways in multiple regulatory jurisdictions across the globe.”

Biologics Testing Solutions

Charles River Laboratories provides comprehensive biologics testing, scientific expertise, and regulatory guidance to help keep development programs on track. As a global partner with GMP-compliant facilities across North America and Europe, the company supports biologics and advanced therapy programs across multiple modalities through an integrated, end-to-end approach. By reducing reliance on fragmented vendor networks, Charles River helps minimize operational risk, strengthen regulatory readiness, and accelerate progress toward clinical and commercial approval.

About MEDIPOST

MEDIPOST Co., Ltd. is a commercial-stage biotechnology company developing allogeneic, umbilical cord blood-derived mesenchymal stem/stromal cell (MSC) therapies for degenerative diseases including knee Osteoarthritis. The company has a regulatory-approved allogeneic stem cell product – CARTISTEM® on the market in South Korea with Phase 3 pivotal studies ongoing in Japan and the U.S., and an additional pipeline of regenerative medicine products built on its proprietary stem cell technology platform with a focus on scalable, off-the-shelf therapeutic approaches. Learn more at www.medi-post.com.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

More News From Charles River Laboratories

Back to Newsroom

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.

Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.

Zacks Premium also includes the Zacks Style Scores.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFinding good stocks at good prices, and discovering which companies are trading under their true value, are what value investors like to focus on. So, the Value Style Score takes into account ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to highlight the most attractive and discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum investors, who live by the saying "the trend is your friend," are most interested in taking advantage of upward or downward trends in a stock's price or earnings outlook. Utilizing one-week price change and the monthly percentage change in earnings estimates, among other factors, the Momentum Style Score can help determine favorable times to buy high-momentum stocks.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank, which is a proprietary stock-rating model, employs earnings estimate revisions, or changes to a company's earnings expectations, to make building a winning portfolio easier.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

But it can feel overwhelming to pick the right stocks for you and your investing goals with over 800 top-rated stocks to choose from.

That's where the Style Scores come in.

To have the best chance of big returns, you'll want to always consider stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B, which will give you the highest probability of success. If you're looking at stocks with a #3 (Hold) rank, it's important they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Charles River Laboratories (CRL - Free Report) Headquartered in Wilmington, MA, Charles River Laboratories International, Inc. (CRL - Free Report) is a full service, early-stage contract research organization (CRO). The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts.

CRL is a #3 (Hold) on the Zacks Rank, with a VGM Score of B.

It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 13.83; value investors should take notice.

Eight analysts revised their earnings estimate higher in the last 60 days for fiscal 2026, while the Zacks Consensus Estimate has increased $0.11 to $11.02 per share. CRL also boasts an average earnings surprise of +9.3%.

With a solid Zacks Rank and top-tier Value and VGM Style Scores, CRL should be on investors' short list.

Charles River Laboratories International, Inc. (NYSE: CRL) announced today that it will present at the William Blair 46th Annual Growth Stock Conference on Tuesday, June 2nd, at 10:00 a.m. CT (11:00 a.m. ET), and at the Jefferies Global Healthcare Conference on Wednesday, June 3rd, at 9:55 a.m. ET. Management will present an overview of Charles River’s strategic focus, business developments, and recent trends.

A live webcast of each presentation will be available through a link that will be posted on the Investor Relations section of the Charles River website at ir.criver.com. A webcast replay will be accessible through the same website after each presentation and will remain available for approximately two weeks.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260601680494/en/

BOSTON--(BUSINESS WIRE)--Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced that the Company will participate in the Sidoti Small-Cap Virtual Conference on June 17 and 18, 2026. CRA Chairman and Chief Executive Officer Paul Maleh is scheduled to present at 10:00 a.m. EDT on Wednesday, June 17. A live webcast will be available on the Company's investor relations website. An archived replay will be avai.